IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
Discussing borderless private- public partnerships to achieve the target of developing 17 new drugs by 2020
The Ministry of Health and Welfare said it held on September 12 a seminar ‘Partnerships in Global Health R&D’ to help assist acceleration of the Korean pharmaceutical industry’s advance into the global new drug and vaccine markets.
The global vaccine market is growing robustly at an annual rate of 11 percent since 2010 and expected to reach 114.2 trillion won in 2023 (GB Research), while the Korean vaccine market, which was worth about 700 billion won in 2014, is also fast expanding at an annual rate of 8 percent. The ratio of domestic vaccine supply relative to domestic needs only amounts about 39 percent as of 2016 (based on the type of vaccines), while the nation’s vaccine export only came to 232.7 billion won as of 2015.
The market for drugs considered as essential public goods is also projected to grow at an annual average rate of 5 percent to 10 percent, primarily in the Asia-Africa (including Australia) and Latin America (Europe: 1~4%, Japan -1~2%) regions. As such, it is urgently necessary (for Korea) to make investment in development of vaccines and new drugs through strategic alliances with international organization(s) with experience in technology and entry into markets, and network with various health authorities of different countries.
Through today’s seminar, the government, international organization(s) such as the Bill & Melinda Gates Foundation and IVI, and Korean companies discussed ways of global private-public partnerships aimed at accelerating investment in vaccines and new drugs and access to the global market. Notably, the Japan Global Health Innovative Technology (GHIT) fund model was explained in details, which was followed by in-depth discussions about the establishment of a private-public fund in the form of a matching fund, and about a model of cooperation with non-profit international organizations that assists individual companies, and the entire process ranging from R&D to access to the global market.
Vice Health and Welfare Minister Bang Moon-kyu said, “If a ‘Korean style global private-public partnership fund is launched,’ it will not only be able to accelerate development of global vaccines and drugs, and development of related industries, but also to improve the national image through expansion of humanitarian assistance to the public sector vaccine and pharmaceutical market.” He added, “Since officials from the Gates Foundation, IVI and Korean companies have gathered today, I hope that the formation of Korean GHIT be materialized in the near future.”
In her congratulatory remarks, Rep. Park In-sook of the ruling Saenuri Party said, “Attention and alert is increasing on infectious diseases of developing countries due to climate change and increased overseas travels, with cholera cases reported in Korea for the first time in 15 years,” adding, “If Korean companies seeking to access the global market can contribute to improving global health and enhance the nation’s international stature through cooperation with international organizations, it will be a smartest strategy for development of the health industry.”
In interviews, IVI Director General Jerome Kim, and Andrea Lucard, Vice chief of MMV, said, “We are aware of benefits that global private-public partnerships provide us” stressing, “We hope to see keen attention and proactive participation by Korean companies with potential and the government.”
Lee Dong-wook, director-general of the health industry policy at the ministry, said, “Today’s seminar is a follow-up measure for the comprehensive development strategy for the health industry (2016-2020), which was announced on September 9,” adding, “The launch of a Korean style private-public partnership will be the key to achieving the goal of developing 17 global new drugs by 2020,” adding, “When considering the trend of the public sector vaccine market as an emerging market, and unprecedentedly strong interest in Korea from overseas research funds and international organizations including the Gates Foundation, now is the right timing for investment,” urging keen attention and active participation by interested parties in Korea and overseas.